Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate [0.03%]
新型AXL特异性条件激活生物药物抗体偶联物mecbotamab vedotin（BA3011）的药代动力学/药效学引导的概念验证研究
Hwai Wen Chang,Jing Wang,Haizhen Liu et al.
Hwai Wen Chang et al.
Background: AXL, a tyrosine kinase receptor, is over-expressed in many solid and hematologic cancers, promoting progression and poor clinical outcomes. It also contributes to resistance against chemotherapeutic agents, es...
Qirui Fan,Hu Chen,Guoguang Wei et al.
Qirui Fan et al.
Antibody-drug conjugates (ADCs) have gained significant attention in biotherapeutics after several years of steady development. Among the multiple factors influencing ADC design, the conjugation method is one of the most critical parameters...
Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors [0.03%]
抗体偶联药物非临床及临床毒性概览及相关影响因素
Yumei Cheng,Jing Lu,Chonghao Zhang et al.
Yumei Cheng et al.
An antibody-drug conjugate (ADC), consisting of an antibody, a chemical linker, and a payload, can selectively deliver a highly cytotoxic payload to cancer cells and minimize the systemic toxicity of the payload by harnessing the selectivit...
A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade [0.03%]
过去十年禽类抗体(IgY)治疗人类细菌感染的系统评价
Zahra Esmaeili,Sara Kamal Shahsavar,Kiarash Ghazvini
Zahra Esmaeili
The overuse of antibiotics worldwide, especially during the Coronavirus pandemic, has raised concerns about the rise of antibiotic resistance and its side effects. Immunoglobulin Y, a natural protein that specifically targets foreign antige...
Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development [0.03%]
抗体药物偶联物制剂开发的基本属性和主要研究领域
Lili Wen,Yuanyuan Zhang,Chenxi Sun et al.
Lili Wen et al.
Antibody-drug conjugates (ADCs) have emerged as a rapidly expanding class of therapeutics driven by their superior specificity and clinical efficacy. 14 out of 16 commercially approved ADCs are formulated as lyophilized forms because ADC is...
Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality [0.03%]
抗体治疗中的FCγ受体多态性及其对提高产品质量的生物检测试验开发的影响
Julianne D Twomey,Sasha George,Baolin Zhang
Julianne D Twomey
The effectiveness of therapeutic antibodies is often associated with their Fc-mediated effector functions, such as antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. These functions rely on interactions b...
Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication [0.03%]
超越ADCs：利用双特异性抗体直接诱导凋亡进行肿瘤的靶向根除
Victor S Goldmacher,Iosif M Gershteyn,Yelena Kovtun
Victor S Goldmacher
Bispecific apoptosis triggers (BATs) are innovative bispecific antibodies designed to simultaneously target both a tumor-associated antigen and a cancer cell's death receptor, thereby directly activating the extrinsic apoptotic pathway to i...
Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review [0.03%]
单克隆抗体治疗系统性红斑狼疮的现状与开发进展：综述
Alexander Blagov,Nikolay Orekhov,Alexey Churov et al.
Alexander Blagov et al.
The development of targeted drugs for the treatment of systemic lupus erythematosus (SLE) is a promising area of research because targeted drugs are associated with a lower risk of severe side effects than systemic drugs. There are only two...
Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research [0.03%]
近红外光免疫疗法：癌症研究中的机制、应用及未来展望
Derek Allen,Madeline JoAnna Szoo,Tessa D van Bergen et al.
Derek Allen et al.
Photoimmunotherapy (PIT) involves the targeted delivery of a photosensitizer through antibody conjugation, which, upon binding to its cellular target and activation by external irradiation, induces localized toxicity. This approach addresse...
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule [0.03%]
通过精确表位测定和利用CD30分子的结构特征从激动抗体生成抗对立双特异性抗CD30抗体
Hiroki Akiba,Tomoko Ise,Reiko Satoh et al.
Hiroki Akiba et al.
Background: CD30 is a member of the tumor necrosis factor receptor superfamily. Recently, blocking CD30-dependent intracellular signaling has emerged as potential strategy for immunological regulation. Development of anti...